Trump administration announces funding for PTSD research on ibogaineWIRED investigation examines Jensen Huang's comments on defining women's power in techWalmart launches early Black Friday promotions on select giftsMint Mobile offers $500 discount on select new phones for new customers signing up for a yearRussia and Iran criticize U.S. Caspian task force amid reports of joint sanction evasion effortsNewly elected US lawmakers pose for traditional group photo at Capitol ahead of 120th Congress openingUS existing home sales drop to lowest monthly level in yearsPro-Palestine philanthropist faces US extradition hearing in SpainLewisham Islamic Centre criticizes charity watchdog over warning on Palestine commentsSenegalese wrestlers succeed in beach wrestling at Dakar Youth OlympicsUS nonprofits file lawsuit seeking pause on advanced AI model trainingDemocrats convene in Denver to discuss party direction after midterm victoriesUS releases report on $12bn from Venezuelan oil, mineral resourcesPope Leo XIV urges Catholic Church to address clergy sexual abuseShooting near White House results in death, suspect later found dead
Back to event

Medical Devices; Orthopedic Devices; Classification of the Wearable Vibration Device for Orthopedic Use

By Drug Administration, Human Services Department, Food, Health · Nov 4, 2026, 11:00 PM CST

Read full article at Federal Register
The Food and Drug Administration (FDA) is classifying the wearable vibration device for orthopedic use into class II (special controls). The special controls that apply to the device type are identified in this order and will be part of the codified language for classification of the wearable vibration device for orthopedic use. We are taking this action because we have determined that classifying

Excerpt shown under fair-use limits. Full text remains with the original publisher.

People in this coverage

Explore their history and attributable record. Being mentioned does not imply endorsement.

Layer 1 · Claims & fact checks

AI analysis

Layer 2 · Biblical perspective

Biblical interpretation
INSUFFICIENT CONTEXT
Read the biblical analysis

Layer 3 · Reporting analysis

AI analysis

Agency framingThe FDA frames the classification as a protective measure for safety and effectiveness, positioning the decision as evidence‑based.

Benefit emphasisThe agency highlights anticipated patient benefits and reduced regulatory burden, presenting the classification as a win‑win for innovation and public health.

Context

AI analysis

Missing context

The notice does not provide details about the specific special controls, the criteria used to determine Class II status, or any timeline for implementation and compliance by manufacturers.

Important context

Class II designation indicates that the device is subject to special controls in addition to general controls, which typically include performance standards, post‑market surveillance, and labeling requirements. This classification can affect how quickly the device reaches the market and the regulatory obligations of manufacturers.

Opinion vs. reporting

AI analysis

The text is primarily reporting factual regulatory action by the FDA; it contains no overt opinion, only statements of intent and expected outcomes presented as the agency’s rationale.